Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVO
Alvotech
$4.12
-4.0%
$5.14
$2.94
▼
$6.53
$1.24B0.24790,444 shs826,571 shs
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$2.50
+2.3%
$3.05
$1.69
▼
$5.17
$327.64M3.162.67 million shs3.63 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$7.47
-3.2%
$10.34
$6.24
▼
$13.39
$1.23B2.655.25 million shs4.73 million shs
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$3.72
-1.3%
$4.38
$3.45
▼
$7.30
$1.21B1.363.09 million shs3.15 million shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVO
Alvotech
-5.71%-8.14%-16.21%-3.16%-17.97%
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-1.21%-11.91%-22.78%-39.00%-2.40%
Novavax, Inc. stock logo
NVAX
Novavax
-3.02%-11.87%-32.46%-13.65%+21.77%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-5.51%-10.45%-8.27%-38.10%-5.99%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVO
Alvotech
$4.12
-4.0%
$5.14
$2.94
▼
$6.53
$1.24B0.24790,444 shs826,571 shs
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$2.50
+2.3%
$3.05
$1.69
▼
$5.17
$327.64M3.162.67 million shs3.63 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$7.47
-3.2%
$10.34
$6.24
▼
$13.39
$1.23B2.655.25 million shs4.73 million shs
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$3.72
-1.3%
$4.38
$3.45
▼
$7.30
$1.21B1.363.09 million shs3.15 million shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVO
Alvotech
-5.71%-8.14%-16.21%-3.16%-17.97%
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-1.21%-11.91%-22.78%-39.00%-2.40%
Novavax, Inc. stock logo
NVAX
Novavax
-3.02%-11.87%-32.46%-13.65%+21.77%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-5.51%-10.45%-8.27%-38.10%-5.99%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alvotech stock logo
ALVO
Alvotech
2.57
Moderate Buy$8.40103.88% Upside
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
2.57
Moderate Buy$8.50240.68% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.33
Hold$13.6082.06% Upside
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.00
Buy$12.75242.74% Upside

Current Analyst Ratings Breakdown

Latest CCCC, NVAX, TSHA, and ALVO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
Alvotech stock logo
ALVO
Alvotech
UpgradeStrong Sell ➝ Hold
11/10/2026
Alvotech stock logo
ALVO
Alvotech
Initiated CoverageBuy$9.00
11/6/2026
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
Initiated CoverageBuy$7.00 ➝ $6.00
11/6/2026
Novavax, Inc. stock logo
NVAX
Novavax
Reiterated RatingBuy$18.00 ➝ $16.00
11/4/2026
Alvotech stock logo
ALVO
Alvotech
UpgradeSell (E+) ➝ Sell (D-)
11/2/2026
Novavax, Inc. stock logo
NVAX
Novavax
Reiterated RatingSell (D)
11/2/2026
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
DowngradeStrong-Buy ➝ Hold
10/28/2026
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
Initiated CoverageBuy$11.00
10/27/2026
Novavax, Inc. stock logo
NVAX
Novavax
Reiterated RatingOverweight
10/23/2026
Alvotech stock logo
ALVO
Alvotech
DowngradeSell (D-) ➝ Sell (E+)
10/20/2026
Alvotech stock logo
ALVO
Alvotech
DowngradeHold ➝ Strong Sell
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alvotech stock logo
ALVO
Alvotech
$588.90M2.11$0.20 per share20.88($0.89) per share-4.63
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$35.95M9.11N/AN/A$1.74 per share1.43
Novavax, Inc. stock logo
NVAX
Novavax
$1.12B1.10$3.29 per share2.27($1.31) per share-5.70
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$9.77M124.15N/AN/A$1.09 per share3.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alvotech stock logo
ALVO
Alvotech
$27.92M-$0.82N/A15.26N/A-50.62%N/A-11.71%N/A
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$104.99M-$0.72N/AN/AN/A-282.22%-37.71%-26.42%N/A
Novavax, Inc. stock logo
NVAX
Novavax
$440.30M-$0.46N/AN/AN/A-18.64%-14.82%-7.55%N/A
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$109M-$0.43N/AN/AN/AN/A-51.87%-40.29%N/A

Latest CCCC, NVAX, TSHA, and ALVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$0.1286-$0.10+$0.0286-$0.10$0.76 millionN/A
11/11/2026Q3 2026
Alvotech stock logo
ALVO
Alvotech
-$0.0297-$0.03-$0.0003-$0.24$123.45 million$111.60 million
11/5/2026Q3 2026
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$0.1945-$0.16+$0.0345-$0.16$8.52 million$8.47 million
11/5/2026Q3 2026
Novavax, Inc. stock logo
NVAX
Novavax
-$0.3460-$0.19+$0.1560-$0.19$50.42 million$68.30 million
8/20/2026Q2 2026
Alvotech stock logo
ALVO
Alvotech
-$0.0526-$0.11-$0.0574-$0.2230$103.00 million$106.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alvotech stock logo
ALVO
Alvotech
N/AN/AN/AN/AN/A
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alvotech stock logo
ALVO
Alvotech
N/A
1.78
0.94
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/A
5.17
5.17
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.15
2.09
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
0.13
18.56
18.56

Institutional Ownership

CompanyInstitutional Ownership
Alvotech stock logo
ALVO
Alvotech
N/A
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
78.81%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
77.70%

Insider Ownership

CompanyInsider Ownership
Alvotech stock logo
ALVO
Alvotech
0.46%
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
5.60%
Novavax, Inc. stock logo
NVAX
Novavax
1.60%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.48%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alvotech stock logo
ALVO
Alvotech
1,460301.81 million300.42 millionNot Optionable
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
104131.32 million123.96 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
749165.01 million162.37 millionOptionable
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
99326.05 million314.70 millionOptionable

Recent News About These Companies

Taysha Gene Therapies (NASDAQ:TSHA) Upgraded at Wall Street Zen
Taysha (TSHA) Q3 2026 Earnings Call Transcript
Taysha Gene Therapies Q3 Earnings Call Highlights
Taysha Gene Therapies' Q3 Net Loss Widens
Taysha Gene Therapies Q3 2026 earnings preview
Taysha Gene Therapies (TSHA) Stock Looks Rich Against Book Value

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alvotech stock logo

Alvotech NASDAQ:ALVO

$4.12 -0.17 (-3.96%)
Closing price 04:00 PM Eastern
Extended Trading
$4.12 +0.00 (+0.12%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

C4 Therapeutics stock logo

C4 Therapeutics NASDAQ:CCCC

$2.50 +0.06 (+2.25%)
Closing price 03:58 PM Eastern
Extended Trading
$2.46 -0.04 (-1.44%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Novavax stock logo

Novavax NASDAQ:NVAX

$7.47 -0.25 (-3.24%)
Closing price 04:00 PM Eastern
Extended Trading
$7.55 +0.08 (+1.02%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Taysha Gene Therapies stock logo

Taysha Gene Therapies NASDAQ:TSHA

$3.72 -0.05 (-1.33%)
Closing price 04:00 PM Eastern
Extended Trading
$3.71 -0.01 (-0.22%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.